Quantum BioPharma is trading 5.26% up at $3.80, primarily amid biotechnology-sector momentum; no new company-specific announcement was identified for September 22, 2026.
- Biotechnology rose 2.07% during regular trading, supported by optimism around AI-driven drug discovery and positive clinical developments.
- FDA clearance for Lucid-MS Phase 2 trials and Rodman & Renshaw’s Buy rating with an $8 target remain supportive, but are not new today.